Articles
Pembrolizumab versus methotrexate, docetaxel, or
cetuximab for recurrent or metastatic head-and-neck
squamous cell carcinoma (KEYNOTE-040): a randomised,
open-label, phase 3 study
Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach,
Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan Cheng, Ramona F Swaby, Kevin J Harrington, on behalf of the KEYNOTE-040 investigators*
Summary
Background There are few effective treatment options for patients with recurrent or metastatic head-and-neck Published Online
squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. November 30, 2018
We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the treatment of http://dx.doi.org/10.1016/
S0140-6736(18)31999-8
head-and-neck squamous cell carcinoma.
See Online/Comment
http://dx.doi.org/10.1016/
Methods We did a randomised, open-label, phase 3 study at 97 medical centres in 20 countries. Patients with head- S0140-6736(18)32346-8
and-neck squamous cell carcinoma that progressed during or after platinum-containing treatment for recurrent or *Investigators listed in the
metastatic disease (or both), or whose disease recurred or progressed within 3–6 months of previous multimodal appendix
therapy containing platinum for locally advanced disease, were randomly assigned (1:1) in blocks of four per stratum San Diego Moores Cancer
with an interactive voice-response and integrated web-response system to receive pembrolizumab 200 mg every Center, University of California,
San Diego, CA, USA
3 weeks intravenously or investigator’s choice of standard doses of methotrexate, docetaxel, or cetuximab intravenously
(Prof E E W Cohen MD); Centre
(standard-of-care group). The primary endpoint was overall survival in the intention-to-treat population. Safety was
Hospitalier de l’Université de
analysed in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT02252042, and is no Montréal, Montréal, QC,
longer enrolling patients. Canada (D Soulières MD);
Department of Drug
Development and Innovation,
Findings Between Dec 24, 2014, and May 13, 2016, 247 patients were randomly allocated to pembrolizumab and Institut Curie, Paris, France
248 were randomly allocated to standard of care. As of May 15, 2017, 181 (73%) of 247 patients in the pembrolizumab (Prof C Le Tourneau MD);
group and 207 (83%) of 248 patients in the standard-of-care group had died. Median overall survival in the intention- INSERM U900 Research Unit,
Paris, France
to-treat population was 8·4 months (95% CI 6·4–9·4) with pembrolizumab and 6·9 months (5·9–8·0) with standard
(Prof C Le Tourneau);
of care (hazard ratio 0·80, 0·65–0·98; nominal p=0·0161). Fewer patients treated with pembrolizumab than with Versailles-Saint-Quentin-
standard of care had grade 3 or worse treatment-related adverse events (33 [13%] of 246 vs 85 [36%] of 234). The most en-Yvelines University, Paris,
common treatment-related adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and France (Prof C Le Tourneau);
Instituto Português de
fatigue with standard of care (in 43 [18%]). Treatment-related death occurred in four patients treated with
Oncologia do Porto Francisco
pembrolizumab (unspecified cause, large intestine perforation, malignant neoplasm progression, and Stevens- Gentil, Porto, Portugal
Johnson syndrome) and two patients treated with standard of care (malignant neoplasm progression and pneumonia). (J Dinis MD); Fondazione IRCCS
Istituto Nazionale dei Tumori,
Milan, Italy (Prof L Licitra MD);
Interpretation The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab
University of Milan, Milan, Italy
in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of (Prof L Licitra); Samsung
pembrolizumab as a monotherapy and as part of combination therapy in earlier stages of disease. Medical Centre, Seoul,
South Korea (Prof M-J Ahn MD);
Hospital Universitario Ramón y
Funding Merck Sharp & Dohme, a subsidiary of Merck & Co.
Cajal, Madrid, Spain
(A Soria MD); Cliniques
Copyright © 2018 Elsevier Ltd. All rights reserved. Universitaires Saint-Luc,
Brussels, Belgium
(Prof J-P Machiels MD);
Introduction patients whose disease pro gressed more than 6 months
Université Catholique de
Despite multimodal therapy including platinum-based after receiving a platinum-containing chemoradiotherapy Louvain, Louvain-la-Neuve,
chemoradiotherapy, more than 50% of patients with regimen ad mi nistered with curative intent.4 Until 2017, Belgium (Prof J-P Machiels);
loco regionally advanced squamous cell carcinoma of the treatment options for recurrent and metastatic disease Hôpitaux Universitaires de
Genève, Geneva, Switzerland
head and neck have recurrence or develop metastases following progression on a platinum-based regimen
(N Mach MD); Fox Chase Cancer
(or both) within 3 years of treatment.1–3 Platinum-based were limited to single-agent chemotherapy or cetuximab, Center, Philadelphia, PA, USA
combination chemotherapy regimens and cetuximab which yield a median overall survival of 7 months (currently affiliated with
Johns Hopkins Sidney Kimmel
are commonly used in the first-line recurrent and or less.1,2,5–7
Comprehensive Cancer Center,
metastatic settings.1,2 The EXTREME regimen, which Inhibitors of the programmed death 1 (PD-1) path-
Baltimore, MD, USA)
consists of platinum, fluorouracil, and cetuximab, is way, which is implicated in tumour immune escape, (R Mehra MD); Yale University
approved in many countries for first-line treatment of have emerged as valid treatment options in patients School of Medicine and Yale
www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8 1
Articles
Cancer Center, New Haven, CT,
USA (Prof B Burtness MD); Research in context
Merck & Co, Kenilworth, NJ,
Evidence before this study for recurrent or metastatic squamous cell carcinoma of the
USA (P Zhang PhD, J Cheng MD,
R F Swaby MD); The Institute of We searched PubMed on April 11, 2018, using the terms “PD-1”, head and neck. Pembrolizumab provides a clinically
Cancer Research, London, UK “PD-L1”, “MK-3475”, “lambrolizumab”, “pembrolizumab”, meaningful prolongation of overall survival and has a
(Prof K J Harrington PhD); and “Keytruda”, “BMS-936558”, “nivolumab”, “Opdivo”, favourable safety profile compared with standard-of-care
The Royal Marsden NHS
“MPDL3280A”, “atezolizumab”, “Tecentriq”, “MEDI4736”, therapy with methotrexate, docetaxel, or cetuximab. There
Foundation Trust, National
Institute of Health Research “durvalumab”, “Imfinzi”, “MSB0010718C”, “avelumab”, or was a clear relationship between higher PD-L1 expression and
Biomedical Research Centre, “Bavencio” and “head and neck cancer”. We applied no time the benefit of pembrolizumab relative to standard-of-care
London, UK (Prof K J Harrington)
limits or language restrictions to the search. We also searched therapy. Receipt of an immune checkpoint inhibitor by
Correspondence to: the abstracts for the 2016 and 2017 American Society of Clinical patients in the standard-of-care group appeared to decrease
Prof Ezra E W Cohen, San Diego
Oncology Annual Meeting and the 2016 and 2017 European the treatment effect of pembrolizumab, a finding that has
Moores Cancer Center, University
of California, San Diego, Society for Medical Oncology Congress using the same search implications for future oncology studies, particularly those
CA 92093, USA terms to identify results of any clinical trials that were not yet done in patients with cancer for which immune checkpoint
ecohen@ucsd.edu published in the peer-reviewed literature. We identified one inhibitors have received regulatory approval.
randomised phase 3 trial of anti-programmed death 1 (PD-1) or
Implications of all the available evidence
anti-programmed death ligand 1 (PD-L1) monotherapy for
Anti-PD-1 and anti-PD-L1 monotherapy have a favourable
squamous cell carcinoma of the head and neck—the
benefit-to-risk profile in patients with recurrent or metastatic
CheckMate 141 study of nivolumab versus investigator’s choice
squamous cell carcinoma of the head and neck that progress
of docetaxel, methotrexate, or cetuximab for patients with
after platinum-based chemotherapy. The benefit of
recurrent or metastatic disease following platinum-based
pembrolizumab monotherapy appears to be greater in
chemotherapy. Phase 1 and phase 2 studies of anti-PD-1 or
patients whose tumours express PD-L1 than in patients
anti-PD-L1 monotherapy for recurrent or metastatic squamous
whose tumours do not express the ligand. The survival benefit
cell carcinoma of the head and neck were identified, including
and safety profile of monotherapy with anti-PD-1 and anti-
the phase 1 KEYNOTE-012 and phase 2 KEYNOTE-055 studies of
PD-L1 therapies in the recurrent or metastatic setting support
pembrolizumab, a phase 1 study of atezolizumab
the evaluation of monotherapy in earlier stages of disease
(NCT01375842), and the phase 2 HAWK study of durvalumab.
and the evaluation of combination regimens that include
Added value of this study PD-1 and PD-L1 inhibitors.
To our knowledge, these data are the first published report of
a randomised, controlled trial of pembrolizumab as therapy
with squamous cell carcinoma of the head and neck on platinum-containing treatment for recurrent or meta-
the basis of their antitumour activity and safety profiles.8–14 static disease (or both) or had recurrence or progression
The anti-PD-1 monoclonal antibody pembrolizumab within 3–6 months of previous multimodal therapy
had a manageable safety profile and produced objective containing platinum for locally advanced disease;
responses in 16–18% of patients with recurr- received two or fewer lines of therapy for recurrent or
ent or metastatic head-and-neck squamous cell carci- metastatic disease; had known human papilloma virus
noma in the phase 1b KEYNOTE-0128,9 and phase 2 (HPV) p16 status for orop haryngeal cancer; had known
KEYNOTE-05512 studies. On the basis of these data, we programmed death ligand 1 (PD-L1) expression status;
initiated the international, randomised, open-label, phase had at least one measurable lesion according to the
3 KEYNOTE-040 trial to compare the efficacy and safety Response Evaluation Criteria in Solid Tumors (RECIST),
of pembrolizumab with those of an investigator’s choice version 1.1;15 and had an Eastern Cooperative Oncology
of methotrexate, docetaxel, or cetuximab (standard of Group (ECOG) per for mance status score of 0 or 1
care) in patients with recurrent or metastatic squamous (on a five-point scale, with 0 indicating no symptoms
cell carcinoma of the head and neck that progressed and higher numbers indicating greater disability).16
during or after platinum-based chemotherapy. Patients were ineligible if their disease progressed
within 3 months of completing definitive treatment for
Methods locoregionally advanced or recurrent disease or had
Study design and participants received previous immune checkpoint inhibitor therapy.
This randomised, open-label, phase 3 study was done at Full eligibility criteria are listed in the trial protocol,
See Online for appendix 97 medical centres in 20 countries. Patients were eligible which is available in the appendix.
for enrolment if they met the following criteria: aged The trial protocol and all amendments were approved
18 years or older; had histologically or cytologically by the appropriate ethics body at each centre. The study
confirmed squamous cell carcinoma of the oral cavity, was done in accordance with the protocol and its amend-
oropharynx, hypopharynx, or larynx, incurable by local ments and Good Clinical Practice guidelines. All patients
therapies; had disease progression during or after provided written informed consent before enrolment.
2 www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8
Articles
Randomisation Outcomes
Patients were enrolled by the study investigators and The primary endpoint was overall survival, defined as the
randomly allocated in a 1:1 ratio using a central interactive time from randomisation to death from any cause in
voice response and integrated web response system the total population. Secondary endpoints were overall
(Almac Clinical Technologies, Souderton, PA, USA) survival in the popul ation with a PD-L1 combined positive
to receive pembrolizumab or investig ator’s choice of score of 1 or higher and the following endpoints in all
methotrexate, docetaxel, or cetuximab. Randomisation was participants and those with a PD-L1 combined positive
stratified by ECOG performance status (0 vs 1), p16 status score of 1 or higher: safety; progression-free survival,
in the oropharynx (positive vs negative), and PD-L1 tumour defined as the time from randomisation to disease
proportion score (≥50% vs <50%). Treatment was allocated progression or death from any cause, assessed according
in blocks of four in each stratum. The allocation schedule to RECIST version 1.115 and modified RECIST (which is
was generated by the system vendor using a computerised the same as RECIST version 1.1 except that a confirmatory
random list generator. Neither patients nor investigators assessment of disease progression done at least 4 weeks
were masked to group assignment. after the initial progressive disease assessment is
required) by masked, independent central radiological
Procedures review; objective response rate, defined as the percentage
Patients assigned to pembrolizumab received 200 mg of patients who had a complete or partial response,
every 3 weeks intravenously. Those assigned to investi- regardless of confirmation, assessed according to RECIST
gator’s choice received either methotrexate 40 mg/m² version 1.1 by masked, indepen dent central radiological
per week intravenously (could be increased to 60 mg/m² review; duration of confirmed response, defined as
per week in the absence of toxicity), docetaxel the time from the first documentation of complete or
75 mg/m² every 3 weeks intravenously, or cetuximab partial response to disease progression or death, assessed
250 mg/m² per week intravenously following a loading according to RECIST version 1.1 by masked, independent
dose of 400 mg/m². Patients received treatment until central radiological review; and time to progression,
disease progression, development of unacceptable defined as the time from randomisat ion to first
toxicity, withdrawal of consent, or physician decision; the documented disease progression, assessed according to
maximum duration of pembrolizumab treatment was RECIST version 1.1 by masked, independent central
24 months. Clinically stable patients with radiological radiological review. Protocol-specified exploratory end-
disease progression could continue study treatment until points included overall and progression-free survival and
pro gression was confirmed on a scan obtained at least the proportion of patients with an objective response in
4 weeks later. There was no planned crossover on disease the population with a PD-L1 tumour proportion score of
progression. Tumour imaging was done at baseline, 50% or higher. The full list of exploratory endpoints is
week 9, then every 6 weeks during year 1 and every available in the protocol.
9 weeks thereafter. Patients were contacted every
12 weeks to assess survival during follow-up. Adverse Statistical analysis
events and laboratory abnormalities were collected The protocol specified two interim analyses and a final
throughout treatment and for 30 days thereafter (90 days analysis. The independent data monitoring committee
for seri ous adverse events and those of special interest to (appendix) recommended that the study continue as
pembrolizumab treatment) and graded using the planned after reviewing the results of both interim
National Cancer Institute Common Terminology Criteria analyses, which were done by an unmasked statistician.
for Adverse Events, version 4.0. The protocol-specified final analysis was planned for
Oropharyngeal p16 status was assessed as a surrogate when approximately 340 deaths had occurred. Assuming
of HPV association using the CINtec p16 Histology assay median overall survival of 6·2 months in the standard-of-
(Ventana Medical Systems, Tucson, AZ, USA) with a care group and 340 total events at final analysis, we
cutoff point for positivity of 70% of cells. PD-L1 expression calculated that enrolment of 466 patients would provide
was assessed at a central laboratory in formalin-fixed the study with 90% power to show a hazard ratio (HR) for
tumour samples during screening using the PD-L1 IHC death of 0·70 or better for the comparison of overall
22C3 pharmDx assay (Agilent Technologies, Carpinteria, survival in the pembrolizumab group versus the standard-
CA, USA). Expression was categorised by the tumour of-care group in the total population. The family-wise
proportion score, defined as the percentage of tumour type I error rate was strictly controlled at a one-sided α
cells with membranous PD-L1 staining, and by the of 0·025 using the Hwang-Shih-DeCani α-spending
combined positive score, defined as the number of function with a γ parameter of –4. α was allocated in a
PD-L1-positive cells (tumour cells, lymphocytes, and stepwise manner starting with the comparison of overall
macro phages) divided by the total number of tumour survival in the total population (appendix). The protocol-
cells multiplied by 100. The combined positive score was specified final analysis was done on the basis of a data
previously reported as a percentage but is now reported cutoff date of May 15, 2017 (efficacy boundary for overall
as a unitless measure. survival in the total population, one-sided α of 0·0175). At
www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8 3
Articles
Overall survival, progression-free survival, objective
699 patients screened response rate, and time to progression were assessed
in the intention-to-treat population, which included all
patients randomly allocated to study treatment. Duration
495 randomly assigned
of response was analysed in all patients who had a best
response of complete or partial response. Safety was
assessed in the as-treated population, which included all
247 allocated to 248 allocated to standard patients who received at least one dose of study treatment.
pembrolizumab* of care†
All statistical analyses were done using SAS, version 9.4.
65 methotrexate
110 docetaxel Overall survival, progression-free survival, and duration of
73 cetuximab response were estimated using the Kaplan-Meier method.
Data for patients who were alive or lost to follow-up were
censored at the time of last contact for estimation of
1 did not receive assigned 14 did not receive assigned
treatment treatment overall survival. Data for patients without disease pro-
1 adverse event 10 withdrew consent gression or who were lost to follow-up were censored
preventing receipt of 3 had clinical
first dose deterioration at the time of last tumour imaging for estimation of
1 lost to follow-up progression-free survival. Data for patients who were alive
before receiving first
without evidence of disease progression who discontinued
dose
the study without radiographical evidence of progression
were censored at the time of the last radiographical
246 received treatment as 234 received treatment as assessment showing response. For both progression-free
assigned assigned
survival and duration of response, data for patients who
64 methotrexate
99 docetaxel started new anticancer therapy without radiographical
71 cetuximab evidence of progression were censored at the time of the
last tumour assessment before new anticancer therapy
223 discontinued 232 discontinued was initiated. Between-group differences in overall and
185 progressive 171 progressive progression-free survival were tested using the stratified
disease‡ disease‡
log-rank test. HRs and their associated 95% CIs were
27 adverse events 37 adverse events
9 withdrawal of 13 withdrawal of calculated using a stratified Cox proportional hazards
consent consent model and Efron’s method of handling ties.17 Differences
1 physician decision 11 physician decision
1 complete response 0 complete response in the proportion of patients with an objective response
were assessed with the stratified Miettinen and Nurminen
method.18 The same stratification factors that were applied
22 remained on treatment 2 remained on treatment to randomisation were applied to all stratified efficacy
1 completed all 35
analyses. A post-hoc exploratory analysis of the interaction
planned doses
of subgroups with treatment effect was done using
the likelihood ratio test. This study is registered with
246 as-treated population 234 as-treated population ClinicalTrials.gov, number NCT02252042.
Role of the funding source
247 intention-to-treat 248 intention-to-treat
population population The funder contributed to study design, data collection,
data analysis, data interpretation, and the writing of this
report. The funder maintained the study database. All
Figure 1: Trial profile
*Major protocol deviations that were determined to be clinically relevant were reported for five patients: receipt of authors had full access to all the data in the study and
three or more previous therapies for advanced disease (n=2), absence of documented failure of platinum therapy had final responsibility for the decision to submit for
(n=2), and progressive disease more than 6 months after platinum-containing multimodal therapy for locally
publication.
advanced disease (n=1). †Major protocol deviations that were determined to be clinically relevant were reported
for five patients: receipt of three or more previous therapies for advanced disease (n=2), progressive disease after
platinum-containing multimodal therapy for locally advanced disease did not occur within 6 months (n=2), and Results
absence of progressive disease documented by radiography (n=1). ‡Includes patients who had radiographic or Between Dec 24, 2014, and May 13, 2016, 495 patients
clinical progression.
were randomly allocated to pembrolizumab (n=247) or to
investigator’s choice of standard-of-care therapy (n=248)
the time of the protocol-specified final analysis, survival at one of 97 sites in 20 countries. Of these participants,
status was not confirmed for 12 patients. A post-hoc 246 in the pembrolizumab group and 234 in the standard-
analysis of overall survival based on the same cutoff date of-care group received study treatment (figure 1). Baseline
(ie, May 15, 2017) was done after confirming the survival demographics and disease characteristics were generally
status of all 495 randomly allocated patients, including balanced between the two treatment groups (table 1). A
the aforementioned 12 patients. PD-L1 combined positive score of 1 or higher was
4 www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8
Articles
observed in 196 (79%) of 247 patients in the pembro-
Pembrolizumab Standard-of-care
lizumab group and 191 (77%) of 248 patients in the
group (n=247) group (n=248)
standard-of-care group. Baseline demographics and
Age (years) 60·0 (55–66) 60·0 (54–66)
disease characteristics for the population with a PD-L1
Sex
combined positive score of 1 or higher and the population
Male 207 (84%) 205 (83%)
with a tumour proportion score of 50% or higher are
Female 40 (16%) 43 (17%)
summarised in the appendix.
Region of enrolment
The median duration of follow-up from randomisation
to data cutoff or death, whichever came first, was Europe 147 (60%) 158 (64%)
7·5 months (IQR 3·4–13·3; 8·4 months [3·3–14·5] in the North America 73 (30%) 60 (24%)
pembrolizumab group and 7·1 months [3·7–12·4] in the Rest of the world 27 (11%) 30 (12%)
standard-of-care group). Overall, 22 (9%) of 247 patients ECOG performance status score
in the pembrolizumab group and two (1%) of 248 patients 0 71 (29%) 67 (27%)
in the standard-of-care group remained on study 1 176 (71%) 180 (73%)
treatment at the time of data cutoff (figure 1). 2 0 1 (<1%)
At the time of the protocol-specified final analysis, which Current or former smoker 179 (72%) 182 (73%)
was based on a data cutoff of May 15, 2017, death had p16 positive in the oropharynx 61 (25%) 58 (23%)
occurred in 179 (72%) of 247 patients in the pembrolizumab PD-L1 tumour proportion score*
group and 198 (80%) of 248 patients in the standard-of- <50% 182 (74%) 180 (72·6%)
care group, with survival status unconfirmed for ≥50% 64 (26%) 65 (26%)
12 patients (three in the pembrolizumab group and nine Missing 1 (<1%) 3 (1%)
in the standard-of-care group). The HR for death for PD-L1 combined positive score†
pembrolizumab versus standard-of-care was 0·82 (95% CI <1 50 (20%) 54 (22%)
0·67–1·01; one-sided p=0·0316; appendix), which did not ≥1 196 (79%) 191 (77%)
meet the efficacy boundary. After confirming the survival Missing 1 (<1%) 3 (1%)
status of the 12 outstanding patients based on the Current disease stage
same data cutoff, the number of deaths in the intention- II 5 (2%) 7 (3%)
to-treat population increased to 181 (73%) of 247 in III 9 (4%) 17 (7%)
the pembrolizumab group and 207 (83%) of 248 in the IV 233 (94%) 224 (90%)
standard-of-care group, and the HR for death was 0·80
Chemotherapy before enrolment
(95% CI 0·65–0·98; nominal p=0·0161; figure 2A).
Curative intent 34 (14%) 40 (16%)
Median overall survival was 8·4 months (95% CI 6·4–9·4)
First-line recurrent or metastatic 141 (57%) 141 (57%)
with pembrolizumab and 6·9 months (5·9–8·0) with
Second-line recurrent or 69 (28%) 64 (26%)
standard of care; the estimated proportion of patients who metastatic
were alive at 12 months was 37·0% (95% CI 31·0–43·1) in Third line recurrent or metastatic 3 (1%) 3 (1%)
the pembrolizumab group and 26·5% (21·2–32·2) in Previous cetuximab 145 (59%) 140 (56%)
the standard-of-care group. The HR for death was similar
Data are median (interquartile range) or n (%). ECOG=Eastern Cooperative
across most subgroups examined, with all 95% CIs
Oncology Group. PD-L1=programmed death ligand 1. *The PD-L1 tumour
overlapping those of the overall population (figure 2B). proportion score was defined as the percentage of tumour cells with membranous
With 300 deaths among the 387 patients with a PD-L1 PD-L1 expression. †The PD-L1 combined positive score was defined as the number
combined positive score of 1 or higher (138 [70%] of 196 in of PD-L1-positive cells (tumour cells, lymphocytes, and macrophages) out of the
total number of tumour cells, multiplied by 100.
the pembrolizumab group and 162 [85%] of 191 in the
standard-of-care group), the HR for death was 0·74 Table 1: Demographic and disease characteristics at baseline in the
intention-to-treat population
(95% CI 0·58–0·93; nominal p=0·0049; figure 3A).
Median overall survival was 8·7 months (95% CI 6·9–11·4)
with pembrolizumab and 7·1 months (5·7–8·3) with effect and PD-L1 combined positive score was 0·07
standard of care. The estimated proportion of patients (figure 2B). In the population with a PD-L1 tumour
surviving at 12 months was 40% (95% CI 33–47) in the proportion score of 50% or higher, 97 deaths occurred in
pembrolizumab group and 26% (20–33) in the standard- 129 patients (41 [64%] of 64 in the pembrolizumab group
of-care. With 84 deaths among the 104 patients with a and 56 [86%] of 65 in the standard-of-care group; HR 0·53,
combined positive score less than 1 (42 [84%] of 50 in the 95% CI 0·35–0·81; nominal p=0·0014; figure 3C). Median
pembrolizumab group and 42 [78%] of 54 in the standard- overall survival was 11·6 months (95% CI 8·3–19·5) with
of-care group), the HR was 1·28 (95% CI 0·80–2·07; pembrolizumab and 6·6 months (4·8–9·2) with standard
p=0·8476) and median overall survival was 6·3 months of care, and estimated overall survival at 12 months
(3·9–8·9) in the pembrolizumab group and 7·0 months was 47% (34–58) and 25% (16–37). In the population with
(5·1–9·0) in the standard-of-care group (figure 3B). The a tumour proportion score of less than 50%, 287 of
nominal, two-sided p value for the interaction of treatment 362 patients (139 [76%] of 182 in the pembrolizumab
www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8 5
Articles
group and 148 [82%] of 180 in the standard-of-care group)
had died (HR 0·93, 95% CI 0·73–1·17; p=0·2675); median
100 overall survival was 6·5 months (95% CI 5·6–8·8) with
90
pembrolizumab and 7·1 months (5·7–8·1) with standard
80
of care (figure 3D). The nominal, two-sided p value for the 70
interaction of treatment effect and PD-L1 tumour 60
50 proportion score was 0·015 (figure 2B).
40 In the intention-to-treat population, 36 of 247 patients
30 in the pembrolizumab group and 25 of 248 in the
20 standard-of-care group had a confirmed or unconfirmed
10 response, resulting in a response rate of 14·6% (95% CI
0
0 5 10 15 20 25 30 10·4–19·6) and 10·1% (6·6–14·5), respectively (nominal
Time (months) p=0·0610; appendix). Among the 26 patients in the
Number at risk
(number censored) pembrolizumab group and 18 patients in the standard-
Pembrolizumab247 (0) 160 (0) 103 (2) 48 (33) 14 (55) 2 (64) 0 (66) of-care group who had a confirmed response, median
Standard of care248 (0) 151 (3) 82 (3) 34 (19) 10 (35) 1 (40) 0 (41)
time to response was 4·5 months (IQR 2·3–6·4) with
pembrolizumab and 2·2 months (2·1–3·5) with stan-
Events/patients Hazard ratio p value
Pembrolizumab Standard of care (95% CI) Interaction dard of care. The median duration of response was
18·4 months (95% CI 5·8–18·4) with pembrolizumab
Overall 181/247 207/248 0·80 (0·65–0·98)
and 5·0 months (3·6–18·8) with standard of care
Sex 0·50
(appendix). The proportion of patients who had an
Male 152/207 177/205 0·77 (0·62–0·96)
Female 29/40 30/43 0·94 (0·54–1·63) objective response in the pembrolizumab group was
Age (years) 0·07 higher in patients whose tumours expressed PD-L1 than
<65 126/165 141/167 0·94 (0·73–1·20) in those whose tumours did not, whereas the proportion
≥65 to <75 40/63 58/69 0·57 (0·37–0·87)
in the standard-of-care group was similar regardless of
≥75 15/19 8/12 1·13 (0·42–3·02
Race 0·63 PD-L1 expression (appendix). Duration of response was
White 149/207 170/207 0·80 (0·64–1·00) not affected by PD-L1 expression, although the medians
Non-white 18/24 22/26 0·93 (0·45–1·92) fluctuated because of the low number of responses
Region of enrolment 0·05
overall (appendix).
Europe 107/147 141/158 0·68 (0·52–0·88)
With 442 events of death or disease progression
North America 52/73 38/60 1·27 (0·82–1·97)
Rest of the world 22/27 28/30 0·67 (0·36–1·26) assessed according to RECIST version 1.1 in the total
ECOG performance status 0·61 population (218 [88%] of 247 in the pembrolizumab group
0 44/71 51/67 0·87 (0·57–1·32) and 224 [90%] of 248 in the standard of care group), no
1 137/176 155/180 0·78 (0·62–0·98)
difference in progression-free survival between treatment
Smoking status 0·87
Current 22/32 31/36 0·71 (0·38–1·31) groups was observed (figure 4). Median progression-free
Former 107/147 120/146 0·78 (0·60–1·02) survival was 2·1 months (95% CI 2·1–2·3) with
Never 52/68 56/66 0·90 (0·60–1·35) pembrolizumab and 2·3 months (2·1–2·8) with standard
p16 status in the oropharynx 0·47
Positive 44/61 45/58 0·97 (0·63–1·49)
Negative 137/186 162/190 0·77 (0·61–0·97)
Previous lines of therapy 0·32
Figure 2: Overall survival in the intention-to-treat population
Curative intent 21/34 33/40 0·77 (0·42–1·43)
Kaplan-Meier estimates of overall survival according to treatment group in the
1 103/141 120/141 0·77 (0·59–1·00) total population (A) and forest plot of the overall survival findings in
≥2 57/72 54/67 0·96 (0·65–1·43) subgroups (B). (A) Tick marks represent patients who had data censored at the
Previous cetuximab 0·38 last time at which they were known to be alive. (B) All subgroups were
Yes 109/145 113/140 0·89 (0·68–1·16) prespecified except for previous cetuximab treatment, age (prespecified
No 72/102 94/108 0·78 (0·56–1·07) categories were ≤65 years vs >65 years), and region of enrolment (prespecified
Choice of chemotherapy 0·32 categories were east Asia vs the rest of the world). Although not a prespecified
Methotrexate 51/70 54/65 0·75 (0·50–1·13) subgroup analysis, the PD-L1 combined positive score breakdown of less than
Docetaxel 94/123 91/110 0·86 (0·64–1·17) 1 versus 1 or higher was included for completeness. *Subgroups are based on
Cetuximab 36/54 62/73 0·56 (0·36–0·89) what the investigator chose before the patient was randomly allocated to
Combined positive score 0·07 treatment with either pembrolizumab or standard of care (investigators were
<1 42/50 42/54 1·28 (0·80–2·10) required to select a standard-of-care therapy for all patients before random
≥1 138/196 62/191 0·74 (0·58–0·93) allocation should they be allocated to that group). The hazard ratios for death
Tumour proportion score 0·015 for the comparison of pembrolizumab versus standard-of-care therapy in all
<50% 139/182 148/180 0·93 (0·73–1·17) subgroups were calculated using a Cox proportional hazards model stratified by
≥50% 41/64 56/65 0·53 (0·35–0·81) the randomisation stratification factors. The interaction of each subgroup with
treatment was a post-hoc exploratory analysis done using the likelihood ratio
0·1 1·0 5·0
test. The two-sided p values are not adjusted for multiplicity and, therefore,
nominal only; small p values suggest that the treatment effect varies across
Favours Favours
pembrolizumab standard of care subgroups. ECOG=Eastern Cooperative Oncology Group. HR=hazard ratio.
PD-L1=programmed death ligand 1.
6 www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8
)%(
lavivrus
llarevO
A
Pembrolizumab
Standard of care
HR 0·80 (95%CI 0·65–0·98);
nominal p=0·0161
B
Articles
PD-L1 combined positive score ≥1 PD-L1 combined positive score <1
100 Pembrolizumab HR 1·28 (95% CI 0·80–2·07);
90 Standard of care nominal p=0·8476
80 HR 0·74 (95% CI 0·58–0·93);
nominal p=0·0049
70
60
50
40
30
20
10
0
0 5 10 15 20 25 30
Number at risk
(number censored)
Pembrolizumab196 (0) 131 (0) 87 (2) 43 (26) 14 (47) 2 (56) 0 (58)
Standard of care191 (0) 115 (3) 63 (3) 28 (13) 8 (25) 1 (28) 0 (29)
PD-L1 tumour proportion score ≥50% PD-L1 tumour proportion score <50%
HR 0·53 (95% CI 0·35–0·81); HR 0·93 (95% CI 0·73–1·17);
nominal p=0·0014 nominal p=0·2675
Figure 3: Overall survival in the intention-to-treat populations according to PD-L1 expression category
Kaplan-Meier estimates of overall survival according to treatment group in the population with a combined positive score of 1 or more (A), the population with a
combined positive score of less than 1 (B), the population with a tumour proportion score of 50% or more (C), and the population with a tumour proportion score of
less than 50% (D). Tick marks represent patients who had data censored at the last time a which they were known to be alive. HR=hazard ratio. PD-L1=programmed
death ligand 1.
of care. Progression-free survival in the population with a of 248 patients in the standard-of-care group received
PD-L1 combined positive score of 1 or higher was similar subsequent therapy, including 11 (4%) of 247 patients in
to that of the total population, whereas progression- the pembrolizumab group and 31 (13%) of 248 patients
free survival was longer with pembrolizumab in the in the standard-of-care group who received subsequent
population with a PD-L1 tumour proportion score of 50% therapy with an immune checkpoint inhibitor
or higher (figure 4); progression-free survival appeared to (appendix). In a post-hoc exploratory analysis in the
be shorter with pembrolizumab than with standard of standard-of-care group, the 31 patients who received
care in the populations with a combined positive score of subsequent immune checkpoint inhibition had longer
less than 1 and tumour proportion score of less than 50%. overall survival than the 70 patients who received other
Median progression-free survival was longer in both subsequent therapy and the 147 patients who received
treatment groups when assessed according to modified no subsequent therapy (med ian overall survival of
RECIST than when assessed with standard RECIST, and 20·1 months vs 9·7 months vs 4·5 months; appendix).
the HRs were close to 1·00 in both the total population In a post-hoc sensitivity analysis in which patients in
and population with a PD-L1 combined positive score of 1 both treatment groups were censored at the time of
or higher (appendix). No difference in time to progression first subsequent immune checkpoint inhibitor, the
assessed according to RECIST version 1.1 was observed in HR for death was 0·72 (95% CI 0·58–0·88; nominal
either the total population or the population with a PD-L1 p=0·0008; appendix). In this analysis, median over-
combined positive score of 1 or higher (appendix). all survival was 8·3 months (95% CI 6·4–9·4) with
In the intention-to-treat population, 84 (34%) of pembrolizumab and 6·6 months (5·4–7·5) with stan-
247 patients in the pembrolizumab group and 101 (41%) dard of care.
www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8 7
)%(
lavivrus
llarevO
A B
0 5 10 15 20 25 30
50 (0) 28 (0) 15 (0) 4 (7) 0 (8) 0 (8) 0 (8)
54 (0) 35 (0) 18 (0) 6 (6) 2 (10) 0 (12) 0 (12)
100
90
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25 30
Time (months)
Number at risk
(number censored)
Pembrolizumab 64 (0) 49 (0) 35 (1) 19 (8) 7 (18) 1 (22) 0 (23)
Standard of care 65 (0) 38 (2) 22 (2) 9 (4) 2 (9) 0 (9) 0 (9)
)%(
lavivrus
llarevO
C D
0 5 10 15 20 25 30
Time (months)
182 (0) 110 (0) 67 (1) 28 (25) 7 (37) 1 (42) 0 (43)
180 (0) 112 (1) 59 (1) 25 (15) 8 (26) 1 (31) 0 (32)
Articles
PD-L1 combined positive score ≥1 PD-L1 combined positive score <1
100 Pembrolizumab
90 Standard of care
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25 30
Number at risk
(number censored)
Pembrolizumab196 (0) 55 (4) 28 (7) 11 (16) 4 (23) 0 (26) 0 (26)
Standard of care191 (0) 42 (11) 17 (16) 8 (19) 1 (21) 0 (21) 0 (21)
PD-L1 tumour proportion score ≥50% PD-L1 tumour proportion score <50%
Figure 4: Progression-free survival in the intention-to-treat population
Kaplan-Meier estimates of progression-free survival according to treatment group in the total population (A), the population with a PD-L1 combined positive score
of 1 or more (B), the population with a combined positive score of less than 1 (C), the population with a PD-L1 tumour proportion score of 50% or more (D), and the
population with a PD-L1 tumour proportion score of less than 50% (E). Tick marks represent patients who had data censored at the last time at which they were
known to be alive and without disease progression. HR=hazard ratio. PD-L1=programmed death ligand 1.
In the as-treated population, treatment-related adverse was similar in patients with a PD-L1 combined positive
events occurred in 155 (63%) of 246 patients treated with score of 1 or higher, with events of any grade occurring in
pembrolizumab and 196 (84%) of 234 patients treated 128 (66%) of 195 patients treated with pembrolizumab
with standard of care (table 2). These events were of and 150 (82%) of 183 patients treated with standard of
grade 3–5 severity in 33 (13%) of 246 patients treated with care, events of grade 3–5 severity occurring in 31 (16%) of
pembrolizumab and 85 (36%) of 234 patients treated 195 patients treated with pembrolizumab and 71 (39%)
with standard of care, and led to treatment discontinuation of 183 patients treated with standard of care, and events
in 15 (6%) of 246 and 12 (5%) of 234 patients, respectively. leading to discontinuation occurring in 13 (7%) of
The incidence of treatment-related adverse events 195 patients treated with pembrolizumab and ten (5%) of
8 www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8
)%(
lavivrus
eerf-noissergorP
A B
0 5 10 15 20 25 30
50 (0) 8 (0) 4 (0) 0 (3) 0 (3) 0 (3) 0 (3)
54 (0) 12 (2) 3 (3) 0 (3) 0 (3) 0 (3) 0 (3)
100
90
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25 30
Time (months)
Number at risk
(number censored)
Pembrolizumab 64 (0) 24 (2) 13 (3) 5 (7) 2 (10) 0 (12) 0 (12)
Standard of care 65 (0) 11 (6) 3 (7) 1 (7) 1 (7) 0 (7) 0 (7)
)%(
lavivrus
eerf-noissergorP
C
0 5 10 15 20 25 30
Time (months)
182 (0) 39 (2) 19 (4) 6 (12) 2 (16) 0 (17) 0 (17)
180 (0) 43 (7) 17 (12) 7 (15) 0 (17) 0 (17) 0 (17)
Total population
100 HR 0·96 (95% CI 0·79–1·16);
90 nominal p=0·3250
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25 30
Time (months)
Number at risk
(number censored)
Pembrolizumab247 (0) 63 (4) 32 (7) 11 (19) 4 (26) 0 (29) 0 (29)
Standard of care248 (0) 54 (13) 20 (19) 8 (22) 1 (24) 0 (24) 0 (24)
)%(
lavivrus
eerf-noissergorP
D
E
Articles
183 patients treated with standard of care. In the total
Pembrolizumab group (n=246) Standard-of-care group (n=234)
population, four patients treated with pembrolizumab
and two patients treated with standard of care died from Any grade Grade 3, 4, or 5 Any grade Grade 3, 4, or 5
adverse events attributed by the investigator to treatment. Treatment-related event*
The treatment-related events that led to death were Any event 155 (63%) 33 (13%) 196 (84%) 85 (36%)
death of unspecified cause, large intestine perforation, Event leading to treatment 15 (6%) 12 (5%) 12 (5%) 9 (4%)
malignant neoplasm progression, and Stevens-Johnson discontinuation
syndrome in the pembrolizumab group and malignant Event leading to death 4 (2%) 4 (2%) 2 (1%) 2 (1%)
neoplasm progression and pneumonia in the standard- Event occurring in 10% or more of patients in either group
of-care group. All but one of the deaths in the pembro- Hypothyroidism 33 (13%) 1 (<1%) 2 (1%) 0
lizumab group occurred in patients with a combined Fatigue 31 (13%) 4 (2%) 43 (18%) 2 (1%)
positive score of 1 or higher. Diarrhoea 20 (8%) 4 (2%) 24 (10%) 1 (<1%)
The most common treatment-related adverse event Rash 19 (8%) 1 (<1%) 34 (15%) 1 (<1%)
was hypothyroidism (33 of 246 patients [13%]) with Asthenia 18 (7%) 1 (<1%) 28 (12%) 4 (2%)
pembrolizumab and fatigue (43 of 234 patients [18%]) Anaemia 17 (7%) 1 (<1%) 33 (14%) 9 (4%)
with standard of care (table 2). In the pembrolizumab Nausea 12 (5%) 0 29 (12%) 1 (<1%)
group, there were four treatment-related adverse events Mucosal inflammation 9 (4%) 1 (<1%) 30 (13%) 5 (2%)
of grade 3–5 severity that occurred in two or more Stomatitis 6 (2%) 1 (<1%) 28 (12%) 11 (5%)
patients each compared with 19 such events in the Neutrophil count decreased 3 (1%) 1 (<1%) 25 (11%) 20 (9%)
standard-of-care group. A summary of all treatment- Alopecia 1 (<1%) 0 25 (11%) 0
related adverse events is available in the appendix. The Event of interest†
adverse events of interest with regard to pembrolizumab,
Any 63 (26%) 11 (4%) 28 (12%) 11 (5%)
regardless of attribution to treatment by the investigator,
Hypothyroidism 37 (15%) 1 (<1%) 9 (4%) 0
are summarised in table 2; one of 246 (<1%) patients had
Pneumonitis 10 (4%) 3 (1%) 3 (1%) 3 (1%)
a grade 5 event (ie, resulting in death), which was a
Infusion-related reaction 8 (3%) 1 (<1%) 7 (3%) 1 (<1%)
severe skin reaction (Stevens-Johnson syndrome).
Severe skin reaction 7 (3%) 4 (2%) 9 (4%) 7 (3%)
Hyperthyroidism 5 (2%) 0 1 (<1%) 0
Discussion
Colitis 2 (1%) 0 1 (<1%) 0
In the randomised, open-label, phase 3 KEYNOTE-040
Guillain-Barré syndrome 2 (1%) 1 (<1%) 0 0
trial, pembrolizumab prolonged overall survival com-
Hepatitis 2 (1%) 1 (<1%) 0 0
pared with investigator’s choice of methotrexate, docetaxel,
or cetuximab in patients with recurrent or metastatic The median duration of treatment in this population was 2·8 months (IQR 1·2–6·8) for pembrolizumab, 1·4 months
(0·7–2·2) for methotrexate, 1·7 months (1·2–3·9) for docetaxel, and 2·3 months (1·6–5·0) for cetuximab. *Events were
squamous cell carcinoma of the head and neck. The
attributed to treatment by the investigator and are listed as indicated by the investigator on the case report form and
benefit of pembrolizumab compared with standard-of- are in descending order of frequency in the pembrolizumab group. †Events of interest are those with an immune-related
care therapy was greater in patients with PD-L1 expression cause and are considered regardless of attribution to study treatment by the investigator. These events are listed in
descending order of frequency in the pembrolizumab group. In addition to the specific preferred terms listed, related
on their tumours or in the tumour microenvironment
terms were also included. Data are number of patients with at least one event (% of patients).
than in those without PD-L1 expression. Pembrolizumab
Table 2: Adverse events in the as-treated population
had a better safety profile than standard of care, with
overall profiles consistent with those previously observed
and no new or unexpected toxicities. The frequency of In a post-hoc exploratory analysis not adjusted for
adverse events of grade 3–5 severity that were attributed to multiplicity, an interaction between the treatment effect
study treatment by the investigator was 2·7 times lower for overall survival and PD-L1 expression appeared to be
with pembrolizumab than with standard of care. More present, such that benefit of pembrolizumab was greater
patients in the pembrolizumab group died from in patients with a combined positive score of 1 or higher
treatment-related adverse events, although the proportion versus those with a combined positive score of less than
was low overall (four [2%] of 246 in the pembrolizumab 1 and those with a tumour proportion score of 50% or
group and two [1%] of 234 in the standard-of-care group). higher versus those with a score of less than 50%.
As previously observed for pembrolizumab and Although not formally tested, the benefits on progression-
other immune checkpoint inhibitors,8–10,12–14 responses to free survival and objective response of pembrolizumab
pembrolizumab were durable. The median duration of com pared with standard-of-care therapy were greater in
response was 18·4 months in the pembrolizumab group, patients whose tumours had PD-L1 expression than in
compared with only 5·0 months in the standard-of-care those who did not express the ligand. Of note, all four
group. Also consistent with previous studies of immune complete responses and 30 of 32 partial responses in the
checkpoint inhibitors in the PD-L1–unselected recurrent pembrolizumab group occurred in patients with a PD-L1
or metastatic setting was the absence of a progression- combined positive score of 1 or higher. Treatment
free survival benefit for pembrolizumab compared with differences were even greater in patients with a PD-L1
standard-of-care therapy.10,19–21 tumour proportion score of 50% or higher. The benefit of
www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8 9
Articles
pembrolizumab has been shown to be enriched in survival at 1 year in the pembrolizumab group of
patients with PD-L1 expression on their tumours in other KEYNOTE-040 (37%) was nearly identical to that of the
advanced malignancies, including non-small-cell lung nivolumab group of CheckMate 141 (36%).10
cancer.22 These data suggest that PD-L1 expression could To further understand the better-than-expected overall
be used as an enrichment strategy in future trials of PD-1 survival observed in patients receiving standard-of-care
blockade. therapy, we did several post-hoc exploratory analyses.
Our data share similarities and differences with those With a minimum follow-up of 12·2 months since the
of the CheckMate 141 study,10 in which the anti-PD-1 last patient enrolled, one or more subsequent immune
monoclonal antibody nivolumab showed superior over- checkpoint inhibitors were received by 13% of patients in
all survival compared with investigator’s choice the standard-of-care group, compared with only 5% of
of methotrexate, docetaxel, or cetuximab in a similar patients in the pembrolizumab group. The patients in
patient population to that enrolled in KEYNOTE-040 the standard-of-care group who received a subsequent
(HR 0·70, 97·73% CI 0·51–0·96, p=0·01). KEYNOTE-040 immune checkpoint inhibitor had a median overall
and CheckMate 141 used the same comparator treatments survival that was two times longer than that of patients
of methotrexate, cetuximab, and docetaxel. Although who received subsequent therapy other than a checkpoint
docetaxel was the chosen chemo therapy for a similar inhibitor, and four times longer than that of patients
proportion of patients in the standard-of-care group in who received no subsequent therapy (20·1 months vs
CheckMate 141 (45%) and KEYNOTE-040 (44%) trials, the 9·7 months vs 4·5 months, respectively). In an analysis
doses administered were different. In CheckMate 141, of overall survival in which patients in both treatment
docetaxel was administered at a dose of 30–40 mg/m² groups were censored at the time at which they started
per week, compared with 75 mg/m² every 3 weeks in subsequent immune checkpoint therapy, median overall
KEYNOTE-040. This diff erence might be relevant given survival in the standard-of-care group decreased to
that data from patients with head-and-neck squamous 6·6 months, which was closer to the predicted overall
cell carcinoma,23,24 non-small-cell lung cancer,25 and pros- survival of 6·2 months based on historical data, and the
tate cancer26 suggest that lower weekly doses of docetaxel HR for death decreased to 0·72 (95% CI 0·58–0·88).
have less efficacy than higher doses administered once These data strongly suggest that subsequent immuno-
every 3 weeks. Although neither KEYNOTE-040 nor therapy influenced outcomes in the standard-of-care
CheckMate 141 was powered to compare outcomes in the group and confounded analysis of overall survival. To the
experimental group with the individual therapies in best of our knowledge, a similar analysis was not done
the standard-of-care group, of note is that the relative in CheckMate-141, in which 5·3% of patients in the
treatment effect of pembrolizumab for overall survival in nivolumab group and 10·1% of patients in the standard-
KEYNOTE-040 was less apparent compared with of-care group received a subsequent checkpoint inhibitor
docetaxel (HR 0·86) than with metho trexate (HR 0·75) with a minimum follow-up of 24·2 months since the last
or cetuximab (HR 0·56); the HRs in the CheckMate 141 patient enrolled.27 Future studies of immunotherapy,
study were 0·82 for docetaxel, 0·64 for methotrexate, particularly those done in patients with cancers for which
and 0·47 for cetuximab. Both KEYNOTE-040 and checkpoint inhibitors are already approved, should
CheckMate 141 enrolled pa tients with locally advanced adequately account for subsequent immunotherapy use
disease that progressed within 6 months of receiving during study design, particularly as this factor pertains to
platinum-based therapy with curative intent. However, power calculations.
because eligibility in KEYNOTE-040 was restricted to The results of this study solidify the role of PD-1
platinum-refractory disease that progressed between checkpoint inhibition in the treatment of head and neck
3 months and 6 months, patients with locally advanced squamous cell carcinoma. The large population size
disease in KEYNOTE-040 might have had a better and ability to collect tissue samples from the majority
prognosis than those in CheckMate 141. Patients whose of participants helped show that PD-L1 expression is a
only previous systemic therapy was definitive and predictive biomarker in this population. Limitations of
administered in the locally advanced setting appeared the data include the inability to assess the efficacy and
to have a greater treatment effect with pembrolizumab safety of pembrolizumab in patients who did not receive
compared with standard of care than the overall study platinum-based therapy, a group that represents a
population. This finding raises speculation not only substantial minority of patients with head and neck
about the reasons that the standard-of-care group in cancer. Moreover, several hypotheses arise from these
KEYNOTE-040 had a higher than expected survival, with data that will need to be tested to explain the outcomes
1 year survival estimates of 26·5% in KEYNOTE-040 and observed in various subgroup analyses, including the
16·6% in CheckMate 141,10 but also the prospect that subgroups based on HPV status and geographical region
adjuvant therapy with PD-1 or PD-L1 inhibitors might be of enrolment.
effective in patients with locally advanced squamous cell Our findings suggest that pembrolizumab provides
carcinoma of the head and neck. Despite the differences a clinically meaningful survival benefit compared with
in eligibility criteria between the studies, the estimated investigator’s choice of methotrexate, docetaxel, or
10 www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8
Articles
cetuximab in patients with recurrent or metastatic head- all outside the submitted work. PZ reports personal fees in the form of
and-neck squamous cell carcinoma that progressed salary as a full-time employee from Merck & Co. JC reports personal
fees in the form of salary as a full-time employee of Merck & Co and
during or after platinum-based therapy. Post-study
stock options from the same company. RFS reports personal fees in
crossover in the standard-of-care group appeared to the form of salary as a full-time employee of Merck & Co and stock
confound the analysis and might have decreased the options from the same company. KJH reports grant support to the
apparent magnitude of the benefit of pembrolizumab on institution from Merck Sharp & Dohme for clinical research related to
the submitted work and fees to the institution from Amgen,
overall survival. Pembrolizumab had a favourable safety
AstraZeneca, Bristol-Myers Squibb, Merck, MSD, Pfizer, and Viralytics
profile compared with standard-of-care therapy, and no and grants to the institution from AstraZeneca and MSD, all outside
new safety signals were observed. Together, these data the submitted work.
support the benefit of pembrolizumab for patients with Acknowledgments
recurrent or metastatic head-and-neck squamous cell This trial was funded by Merck Sharp & Dohme, a subsidiary of
carcinoma. Merck & Co, Kenilworth, NJ, USA (MSD). We thank the patients and
their families and caregivers for participating in this trial, all the
Contributors investigators and site personnel, the staff of Agilent Technologies for
EEWC, BB, JC, and KJH conceived and designed the study. EEWC, developing the PD-L1 IHC 22C3 pharmDx assay, Joy Ge and
J-PM, PZ, JC, RFS, and KJH analysed the data. EEWC, DS, CLT, JD, LL, Christine Gause (MSD) for assistance with statistical analyses,
AS, J-PM, NM, RM, RFS, and KJH acquired the data. EEWC, PZ, RFS, Alba Tuozzo (MSD) for contributions to study conduct, and
and KJH wrote the first draft of the manuscript. EEWC, DS, LL, M-JA, Melanie A Leiby (MSD) for medical writing and editorial assistance.
AS, J-PM, RM, BB, PZ, JC, RFS, and KJH interpreted the data. All
References
authors contributed to reviewing or revising the manuscript and
1 Licitra L, Felip E, Group EGW. Squamous cell carcinoma of the
approved the final version.
head and neck: ESMO clinical recommendations for diagnosis,
Declaration of interests treatment and follow-up. Ann Oncol 2009; 20 (suppl 4): 121–22.
EEWC reports grant support to the institution from Merck Sharp & 2 National Comprehensive Cancer Network I. NCCN clinical practice
Dohme for clinical research related to the submitted work and serving guidelines in oncology (NCCN guidelines): head and neck cancers,
an advisory role for AstraZeneca, Bristol-Myers Squibb, Eisai, Merck, version 2. 2018. https://www.nccn.org/professionals/physician_gls/
pdf/head-and-neck.pdf (accessed Aug 2, 2018).
Human Longevity, and Pfizer, all outside the submitted work.
DS reports grant support to the institution from Merck Sharp & 3 Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC):
Dohme for clinical research related to the submitted work and
a comprehensive analysis by tumour site. Radiother Oncol 2011;
personal fees for advisory board membership from Merck outside the
100: 33–40.
submitted work. CLT reports grant support to the institution from
4 Vermorken JB, Mesia R, Rivera F, et al. Platinum-based
Merck Sharp & Dohme for clinical research related to the submitted
chemotherapy plus cetuximab in head and neck cancer.
work and personal fees for serving as a consultant or adviser or for
N Engl J Med 2008; 359: 1116–27.
lectures from Amgen, Bristol-Myers Squibb, Merck Serono, MSD,
5 Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised
Nanobiotix, Novartis, and Roche, all outside the submitted work.
phase II study comparing docetaxel with methotrexate in patients
JD reports grant support to the institution from Merck Sharp & with recurrent head and neck cancer. Eur J Cancer 2004; 40: 2071–76.
Dohme for clinical research related to the submitted work. LL reports 6 Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J.
grant support to the institution from Merck Sharp & Dohme for Overview of the efficacy of cetuximab in recurrent and/or metastatic
clinical research related to the submitted work and grants to the squamous cell carcinoma of the head and neck in patients who
institution for clinical studies and research from AstraZeneca, previously failed platinum-based therapies. Cancer 2008;
Boehringer Ingelheim, Eisai, Merck-Serono, MSD, Novartis, and 112: 2710–19.
Roche, personal fees for serving as a consultant or advisor or for 7 Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized,
lectures from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer placebo-controlled trial of docetaxel with or without gefitinib in
Ingelheim, Debiopharm, Eisai, Merck Serono, MSD, Novartis, Roche, recurrent or metastatic head and neck cancer: an eastern
and Sobi, and travel support for medical meetings from Bayer, cooperative oncology group trial. J Clin Oncol 2013; 31: 1405–14.
Bristol-Myers Squibb, Debiopharm, Merck-Serono, MSD, and Sobi, 8 Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of
all outside the submitted work. M-JA reports grant support to the pembrolizumab for treatment of recurrent or metastatic squamous
institution from Merck Sharp & Dohme for clinical research related to cell carcinoma of the head and neck (KEYNOTE-012): an open-label,
multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956–65.
the submitted work. AS reports grant support to the institution from
Merck Sharp & Dohme for clinical research related to the submitted 9 Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of
pembrolizumab in biomarker-unselected patients with recurrent
work and personal fees for giving lectures from Bristol-Myers Squibb,
and/or metastatic head and neck squamous cell carcinoma:
Novartis, and Roche, all outside the submitted work. J-PM reports
Results from the phase Ib KEYNOTE-012 expansion cohort.
grant support to the institution from Merck Sharp & Dohme for
J Clin Oncol 2016; 34: 3838–45.
clinical research related to the submitted work and serving as an
10 Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for
uncompensated advisory board member for MSD. NM reports grant
recurrent squamous-cell carcinoma of the head and neck.
support to the institution from Merck Sharp & Dohme for clinical N Engl J Med 2016; 375: 1856–67.
research related to the submitted work. RM reports grant support to
11 Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of
the institution from Merck Sharp & Dohme for clinical research immune escape and implications for immunotherapy in head and
related to the submitted work, previous employment of RM’s spouse at neck squamous cell carcinoma. Eur J Cancer 2017; 76: 152–66.
GlaxoSmithKline, and serving as an advisory board member for Bayer, 12 Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for
Bristol-Myers Squibb, Genentech, and InnatePharma, all outside the platinum- and cetuximab-refractory head and neck cancer: results
submitted work. BB reports research funding to the institution and from a single-arm, phase II study. J Clin Oncol 2017; 35: 1542–49.
receipt of personal fees for serving on a steering committee for the 13 Bahleda R, Braiteh FS, Balmanoukian AS, et al. Long-term safety
work under consideration for publication and research funding to the and clinical outcomes of atezolizumab in head and neck cancer:
institution from Advaxis and Bristol-Myers Squibb, receiving personal phase Ia trial results. Ann Oncol 2017; 28 (suppl 5): 1044O.
fees for serving on a data safety monitoring committee for IDDI, 14 Zandberg D, Algazi A, Jimeno A, et al. Durvalumab for recurrent/
receiving personal fees for serving on an advisory board for metastatic (R/M) head and neck squamous cell carcinoma
AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, (HNSCC): preliminary results from a single-arm, phase 2 study.
and Genentech, and travel support from Boehringer Ingelheim, Ann Oncol 2017; 28 (suppl 5): 1042O.
www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8 11
Articles
15 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response 23 Hitt R, Amador ML, Quintela-Fandino M, et al. Weekly docetaxel in
evaluation criteria in solid tumours: revised RECIST guideline patients with recurrent and/or metastatic squamous cell carcinoma
(version 1.1). Eur J Cancer 2009; 45: 228–47. of the head and neck. Cancer 2006; 106: 106–11.
16 Oken MM, Creech RH, Tormey DC, et al. Toxicity and response 24 Seiwert TY, Cohen EE, Haraf DJ, et al. A phase I trial of docetaxel
criteria of the Eastern Cooperative Oncology group. Am J Clin Oncol based induction and concomitant chemotherapy in patients with
1982; 5: 649–55. locally advanced head and neck cancer. Cancer Invest 2007;
17 Efron B. The efficiency of Cox’s likelihood function for censored 25: 435–44.
data. J Am Stat Assoc 1977; 72: 557–65. 25 Camps C, Massuti B, Jimenez A, et al. Randomized phase III study
18 Miettinen O, Nurminen M. Comparative analysis of two rates. of 3-weekly versus weekly docetaxel in pretreated advanced
Stat Med 1985; 4: 213–26. non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
19 Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Ann Oncol 2006; 17: 467–72.
everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 26 Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or
373: 1803–13. mitoxantrone plus prednisone for advanced prostate cancer.
20 Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel N Engl J Med 2004; 351: 1502–12.
for previously treated, PD-L1-positive, advanced non-small-cell lung 27 Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs
cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; investigator’s choice in recurrent or metastatic squamous cell
387: 1540–50. carcinoma of the head and neck: 2-year long-term survival update of
21 Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second- CheckMate 141 with analyses by tumor PD-L1 expression.
line therapy for advanced urothelial carcinoma. N Engl J Med 2017; Oral Oncol 2018; 81: 45–51.
376: 1015–26.
22 Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment
of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018–28.
12 www.thelancet.com Published online November 30, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31999-8
